文献速递药物不良反应与药物警戒肝肾功能剂量调整

吉西他滨相关血栓性微血管病:法国全国回顾性队列研究

Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.
PubMed 文献 · Br J Clin Pharmacol · 2018-12-18

本研究基于法国药物警戒网络和血栓性微血管病参考中心1998至2015年数据,分析120例吉西他滨相关血栓性微血管病(G-TMA)患者。

要点

  • 水肿和高血压可作为早期监测指标,帮助发现G-TMA。
  • G-TMA常伴严重急性肾损伤(97.4%)且27.8%需透析,死亡率高。

核心结论

  • 该大型队列证实G-TMA病情严重,与严重肾功能衰竭和死亡相关。
  • 水肿和高血压可在吉西他滨治疗患者中监测以早期发现TMA。
  • 血浆置换或依库珠单抗的获益有待进一步研究。

研究设计与样本

  • 法国全国回顾性队列研究,纳入1998至2015年法国药物警戒网络和法国TMA参考中心报告的G-TMA病例及补体替代途径异常检查病例。
  • 共诊断120例G-TMA患者,中位年龄61.5岁。

主要发现

  • 主要症状为水肿56.7%、新发或加重高血压62.2%;溶血性贫血95.6%、血小板减少74.6%。
  • 急性肾损伤97.4%,27.8%需透析;治疗包括血浆置换39.8%、新鲜冰冻血浆21.4%、糖皮质激素15.3%、依库珠单抗5.1%。
  • TMA完全缓解42.1%,血液学缓解23.1%,未改善34.7%;已知生存状态52例中死亡29例(54.7%)。
  • 接受血浆置换者尽管急性肾损伤更重、透析更频繁,缓解率相当但不良事件更多;检查患者中未发现补体替代途径异常。

临床怎么用

  • 吉西他滨治疗期间监测水肿和高血压,警惕G-TMA早期表现。
  • 出现溶血性贫血、血小板减少和急性肾损伤时应考虑G-TMA并及时评估。
  • 血浆置换或依库珠单抗的获益尚需进一步研究,临床决策需权衡。

局限性

  • 回顾性研究设计,可能存在报告偏倚和信息不完整。
  • 生存状态仅已知52例,死亡率数据不完整。
  • 补体替代途径检查仅在部分患者中进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Gemcitabine has been associated with thrombotic microangiopathy (TMA). We conducted a national retrospective study of gemcitabine-associated TMA (G-TMA). METHODS: From 1998 to 2015, all cases of G-TMA reported to the French Pharmacovigilance Network and the French TMA Reference Center, and cases explored for complement alternative pathway abnormalities, were analysed. RESULTS: G-TMA was diagnosed in 120 patients (median age 61.5 years), after a median of 210 days of treatment, and a cumulative dose of 12 941 mg m-2 . Gemcitabine indications were: pancreatic (52.9%), pulmonary (12.6%) and breast (7.6%) cancers, metastatic in 34.2% of cases. Main symptoms were oedema (56.7%) and new-onset or exacerbated hypertension (62.2%). Most patients presented with haemolytic anaemia (95.6%) and thrombocytopenia (74.6%). Acute kidney injury was reported in 97.4% and dialysis was required in 27.8% of patients. Treatment consisted of: plasma exchange (PE; 39.8%), fresh frozen plasma (21.4%), corticosteroids (15.3%) and eculizumab (5.1%). A complete remission of TMA was obtained in 42.1% of patients and haematological remission in 23.1%, while 34.7% did not improve. The survival status was known for 52 patients, with 29 deaths (54.7%). Patients treated with PE, despite a more severe acute kidney injury, requiring dialysis more frequently, displayed comparable rates of remission, but with more adverse events. No abnormality in complement alternative pathway was documented in patients explored. CONCLUSION: This large cohort confirms the severity of G-TMA, associated with severe renal failure and death. Oedema and hypertension could be monitored in patients treated with gemcitabine to detect early TMA. The benefit of PE or eculizumab deserves further investigation.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Daviet F, Rouby F, Poullin P, et al. Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. Br J Clin Pharmacol. 2018. PMID: 30394581. doi:10.1111/bcp.13808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。